Virtual Presentation

Incorporating Molecular Data Into Risk Stratification for AML

Source: Navigating the Therapeutic Pathways for AML and MDS

Incorporating Molecular Data Into Risk Stratification for AML

Faculty:

Steven M. Devine, MD

CREDIT INFORMATION

Release Date: February 12, 2010

Expiration Date: February 11, 2011

Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Explain the relative importance of age, cytogenetics, and molecular markers as prognostic and predictive factors in patients with AML
Articulate the role of allogeneic transplantation in the treatment of patients with AML who are younger than 60 years of age
Describe the influence of donor HLA and KIR genotypes on transplantation outcomes in patients with AML
Restate research directions for allogeneic transplantation in patients older than 60 years of age

CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.